OLIGOMED - Oligonucleotides for Medical Applications
Titolo progetto: OLIGOMED - Oligonucleotides for Medical Applications
Programma di finanziamento: Horizon 2020 - Marie Skłodowska-Curie Innovative Training Networks
Responsabile scientifico: dott. Carlo Vascotto
Ruolo del DAME: partner
Descrizione generale:
The use of synthetic oligonucleotides (ONs, short DNA or RNA strands) in the treatment of genetic diseases is a rapidly growing field, and the most promising alternative to gene therapy or small molecules. Most pharmaceutical companies shift from in-house platform development to product-specific licensing and co-development to get ON based therapies past clinical trials. Therefore there is a growing and currently unmet need for a combined academic and industry-based multidisciplinary research to further advance the field by bringing together the separated and fragmented R&D efforts of diverse ON technologies.
Our European intersectoral and multidisciplinary research and training network for 15 Early Stage Researchers (ESRs) will
deliver:
-highly skilled scientific staff required to fully exploit ON therapeutics for personalised medicine
-top-class training in organic and chemoenzymatic synthesis, ON analysis, and biomedical/medicinal testing
-transferable skills courses, specific industry relevant workshops and public engagement activities
Partner del progetto:
1 UNIVERSITY OF SOUTHAMPTON UK
2 CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR
3 KAROLINSKA INSTITUTET SE
4 KRZYSZTOF KUCHARCZYK TECHNIKI ELEKTROFORETYCZNE SPZOO PL
5 STOCKHOLMS LANS LANDSTING SE
6 UNIVERSITE DE BORDEAUX FR
7 UNIVERSITEIT GENT BE
8 UNIVERSITA DEGLI STUDI DI UDINE IT
9 ASTRAZENECA AB SE
10 THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK
11 SIXFOLD BIOSCIENCE LTD UK
12 RISE RESEARCH INSTITUTES OF SWEDEN AB SE
Date inizio e fine progetto: 01.05.2020 – 30.04.2024
Budget totale del progetto: 4.153.344,12€
Contatti: carlo.vascotto@uniud.it